Hyperglycosylated polypeptide variants and methods of use

摘要: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid agonists, containing one more native non-native glycosylation sites. sites, as well erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation substance across biological barrier pharmaceutical compositions, including oral formulations, the same. further formulations hyperglycosylated protease-resistant, variants, variants lack at least protease cleavage site found in parent polypeptide, thus exhibit increased resistance compared include (1) carbohydrate moiety covalently not protein therapeutic (2) but glycosylated therapeutic. agonist, variant, hyperglycosylated, protease-resistant variant. containers, devices, kits methods involving administering an effective amount composition variant individual need thereof.